pentapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Molecular mass | Approximately 711.9 Da | Free base, calculated value |
| Receptor target | GHS-R1a, the ghrelin receptor | Agonist activity reported |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C-terminal amide |
| Reported selectivity | Little change in ACTH, cortisol, prolactin | Based mainly on animal data |
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
==== COVID-19 ==== Use of the intradermal BCG vaccine may provide protection against COVID-19. However, epidemiologic observations in this respect are ambiguous. The WHO does not recommend its use for prevention as of 12 January 2021. As of January 2021, 20 BCG trials are in various clinical stages. As of October 2022, the results are extremely mixed. A 15-month trial involving people thrice-vaccinated over the two years before the pandemic shows positive results in preventing infection in BCG-naive people with type 1 diabetes. On the other hand, a 5-month trial shows that re-vaccinating with BCG does not help prevent infection in healthcare workers. Both of these trials were double-blind randomized controlled trials (RCTs). A 2024 systmatic review of 12 RCTs reports that BCG does not help protect against COVID-19. Follow up of one of the BCG-COVID trials (BATTLE) shows positive results in preventing long COVID.
=== Treatment === A potential treatment for the high ammonia levels is to give sodium benzoate, which combines with glycine to produce hippurate, at the same time removing an ammonium group. Biotin (vitamin B7) also plays an important role in the functioning of the OTC enzyme and has been shown to reduce ammonia intoxication in animal experiments. Additionally, the use of whole-body therapeutic hypothermia (TH) has been proposed and studied as a treatment. TH is thought to increase the effectiveness of dialysis to extract ammonia from the body.
The shortage of manufacturing facilities for the Il-86 was a problem from the outset: "The rapid modernisation of the Soviet Air Force ... has left limited scope for the expansion of commercial production ... the lack of production capacity is being remedied partly by ... international cooperation." This meant involving the Polish aircraft industry in the project.
Sivasankar and his research team have found that the mechanism behind the puzzling phenomenon is due to long-lived, force-induced hydrogen bonds. Using data from previous experiments, the team used molecular dynamics to discover that two rod-shaped cadherins in an X-dimer formed catch bonds when pulled and in the presence of calcium ions. The calcium ions keep the cadherins rigid, while pulling brings the proteins closer together, allowing for hydrogen bonds to form. The mechanism behind catch bonds helps to explain the biophysics behind cell-cell adhesion. According to the researchers, "Robust cadherin adhesion is essential for maintaining the integrity of tissue such as the skin, blood vessels, cartilage and muscle that are exposed to continuous mechanical assault." The above catch bonds are formed between adhesion receptors and ligands, and among structural molecules and motor proteins, which bear force or generate force in their physiological function. An interesting recent development is the discoveries of catch bonds formed between signaling receptors and their ligands. These include bonds between T cell antigen receptors (TCR) or pre-TCR and peptide presented by major histocompatibility complex (pMHC) molecules, Fc gamma receptor and IgG Fc, and notch receptor and ligands. The presence of catch bonds in the interactions of these signaling (rather than adhesion) receptors have been suggested to be indicative of a possible role of these receptors as mechanoreceptors.
== Instrumentation and Performance == Initially the digital ion trap was constructed in form of a 3D ion trap, where the drive signal was fed to the ring electrode of the trap. Instead of scanning up the RF voltage, in the DIT, the frequency of the rectangular waveform signal is scanned down during a forward mass scan. This avoided the high voltage breakdown which set the upper limitation of a mass scan. Mass range of DIT up to 18,000 Th was demonstrated by use of an atmospheric MALDI ion source and was later expanded to cover m/z of a singly charged antibody at about 900,000 Th by Koichi Tanaka etc. The MOSFET switch circuit is responsible to provide the rectangular wave drive signal. The drive circuit of DIT is much compact compared to the RF generator with LC resonator circuit used for conventional sinusoidal wave ion trap. It also provides the capability of fast start up and fast termination of the waveform, which enables injection and ejection of ion with high efficiency. A field adjusting electrode placed adjacent to the entrance end-cap and biased with certain dc voltages helped to achieve good mass resolution for both forward and reverse mass scans, as well as for precursor isolation. With trapping voltage of +/- 1kV, a zoom scan resolving power of 19,000 was demonstrated.
Sources: en.wikipedia.org
At launch, it received mediocre reviews for its lack of significant gameplay and visual enhancements, although IGN still recommended it. Retrospective reception has been more negative, owing to the game's instability and frequent glitches. The deathmatch mode was ported to Source separately in 2006 as Half-Life Deathmatch: Source. Following the release of the Half-Life 25th anniversary update in 2023, Half-Life: Source was delisted from Steam and does not appear in its search results, it is now bundled for free with Half-Life Deathmatch: Source, which remains available. Black Mesa, a third-party remake of Half-Life developed by Crowbar Collective on the Source engine, was published as a free mod in September 2012 and later approved by Valve for a commercial standalone release.
Obestatin is a hormone that is produced in specialized epithelial cells of the stomach and small intestine of several animals including humans. Obestatin was originally identified as an anorectic peptide, but its effect on food intake remains controversial.
Temperature in the anus (rectum/rectal) is at or over 37.5–38.3 °C (99.5–100.9 °F). An ear (tympanic) or forehead (temporal) temperature may also be used. Temperature in the mouth (oral) is at or over 37.2 °C (99.0 °F) in the morning or over 37.7 °C (99.9 °F) in the afternoon Temperature under the arm (axillary) is usually about 0.6 °C (1.1 °F) below core body temperature. In adults, the normal range of temperatures in healthy individuals is 36.32–37.76 °C (97.4–100.0 °F) (rectal), 35.76–37.52 °C (96.4–99.5 °F) (ear), 35.61–37.61 °C (96.1–99.7 °F) (urine), 35.73–37.41 °C (96.3–99.3 °F) (oral), and 35.01–36.93 °C (95.0–98.5 °F) (axillary), with no significant gender differences. Normal body temperatures vary depending on many factors, including age, sex, time of day, ambient temperature, activity level, and more. Normal daily temperature variation has been described as 0.5 °C (0.9 °F). A raised temperature is not always a fever. For example, the temperature rises in healthy people when they exercise, but this is not considered a fever, as the set point is normal. On the other hand, a "normal" temperature may be a fever, if it is unusually high for that person; for example, medically frail elderly people have a decreased ability to generate body heat, so a "normal" temperature of 37.3 °C (99.1 °F) may represent a clinically significant fever.
=== Bibliography === Arnheim, Daniel D. Dance Injuries: Their Prevention And Care. 3rd ed. Princeton, NJ: Princeton Book Company, 1991. Print. Ashley, Linda. Essential Guide to Dance. 2nd ed. London: Hodder & Stoughton, 2004. Print. ISBN 978-0340803202. Barratt, Marcia, et al. Foundations For Movement. Dubuque, IA: Wm. C. Brown Co., 1964. Print. Berardi, Gigi. Finding Balance. 2nd ed. Routledge, NY: Routledge, 2005. Print. ISBN 978-0415943390. Blakey, W P. Stretching Without Pain. Canada: Twin Eagles Educational & Healing Institute, 1994. Print. ISBN 978-1873017050. Como, William. Raoul Gelabert's anatomy for the dancer with exercises to improve technique and prevent injuries. New York: Danad, 1964; 51-57. ASIN B000XYUX4Q. Dilmen, Nevit. Stretching. 2009. Own Work. Wikimedia Commons. Web. 4 Dec. 2010. Franklin, Eric N. Conditioning for Dance. Champaign, IL: Human Kinetics, 2004. Print. FvS. Split, gymnastics. 2005. Own Work. Wikimedia Commons. Web. 4 Dec. 2010. Liedarback, "General considerations," p. 59. McCharles, Rick. Gymnast jumping on beam. 2008. https://www.flickr.com/photos/71035721@N00/2972933329. Wikimedia Commons. Web. 4 Dec. 2010. Pare, Caroline. Caroline Zhang in 2008 Skate Canada International. 2008. https://web.archive.org/web/20120724082853/http://everythingskating.com/. Wikimedia Commons. Web. 4 Dec. 2010. Reinking, Ann, and Linda Szmyd. The Dancer's Workout. London: Bantam Books, 1984. Print. Ryan, Allan J., and Robert E. Stephens, eds. The Healthy Dancer: Dance Medicine for Dancers. Princeton, NJ: Princeton Book Company, 1987. Print.
Sources: en.wikipedia.org
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.
Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.
Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.